A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density

Open Access

Peer-reviewed

Research Article

Bethany Powell Gray,

Affiliation Department of Internal Medicine and The Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
⨯
Michael J. McGuire,

Affiliation Department of Internal Medicine and The Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
⨯
Kathlynn C. Brown

* E-mail: Kathlynn.Brown@UTSouthwestern.edu

Affiliation Department of Internal Medicine and The Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
⨯

Reader Comments (0)

Liposomes
Is the Subject Area "Liposomes" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Fluorescence imaging
Is the Subject Area "Fluorescence imaging" applicable to this article?

Thanks for your feedback.
In vivo imaging
Is the Subject Area "In vivo imaging" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.